Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair
Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its licensed technology of a new class of PNKP (Polynucleotide Kinase 3'-Phosphatase) inhibitors (the "Technology") which has demonstrated, in a study[1], the ability to enhance the efficacy of cancer killing inhibitors, known as topoisomerase I poisons, in certain cancer treatments. By enhancing cancer cells'...
Read more








